Alison T Stopeck

  • 10598 Citations
  • 40 h-Index
1982 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Alison T Stopeck is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
zoledronic acid Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Bone and Bones Medicine & Life Sciences
Bone Neoplasms Medicine & Life Sciences
Circulating Neoplastic Cells Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1992 2017

Aromatase Inhibitors
Sulindac
Breast
Biomarkers
Breast Neoplasms
Diffusion Magnetic Resonance Imaging
Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Therapeutics
Diffusion Magnetic Resonance Imaging
docetaxel
Water
Drug Therapy
Therapeutics
Cholesterol
Cytokines
LDL Receptors
Liver
Atherosclerosis

Research Output 1982 2019

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer

Segar, J. M., Reed, D., Stopeck, A. T., Livingston, R. B. & Chalasani, P., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access
irinotecan
Etoposide
Breast Neoplasms
Topoisomerase I Inhibitors
Type II DNA Topoisomerase

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Stopeck, A. T., Brufsky, A., Kennedy, L., Bhatta, S., Bhowmik, D., Buchanan, J., Despiegel, N. & Hechmati, G., Jan 1 2019, (Accepted/In press) In : Journal of medical economics.

Research output: Contribution to journalArticle

Open Access
zoledronic acid
Cost-Benefit Analysis
Neoplasm Metastasis
Bone and Bones
Costs and Cost Analysis
2 Citations (Scopus)

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Gonçalves, A., Jerusalem, G., Stopeck, A. T., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B. & Pickett, C. A., Jan 1 2018, (Accepted/In press) In : Clinical Breast Cancer.

Research output: Contribution to journalArticle

Paclitaxel
Breast Neoplasms
Angiopoietin-1
Epidermal Growth Factor Receptor
Angiopoietin-2
3 Citations (Scopus)

Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI

Ding, J., Stopeck, A. T., Gao, Y., Marron, M. T., Wertheim, B. C., Altbach, M. I., Galons, J-P., Roe, D., Wang, F., Maskarinec, G., Thomson, C., Thompson, P. A. & Huang, C., Jan 1 2018, (Accepted/In press) In : Journal of Magnetic Resonance Imaging.

Research output: Contribution to journalArticle

Ionizing Radiation
Fats
Water
Breast Density
Breast
6 Citations (Scopus)

A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen

Thomson, C., Chow, H-H., Wertheim, B. C., Roe, D., Stopeck, A. T., Maskarinec, G., Altbach, M. I., Chalasani, P., Huang, C., Strom, M. B., Galons, J-P. & Thompson, P. A., May 30 2017, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-11 11 p.

Research output: Contribution to journalArticle

Tamoxifen
Tumor Biomarkers
Randomized Controlled Trials
Placebos
Breast Neoplasms